WHO ICTRP trial
Randomized phase III study in elderly patients with a multiple myeloma on the…
NL-OMON25578 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON25578 |
|---|---|
| Public title | Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone. |
| Scientific title | Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone. |
| Primary sponsor | Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center Erasmus MC - Daniel den Hoed Postbus 5201 3008 AE Rotterdam Tel: 010 4391568 Fax: 010 4391028 e-mail: [email protected] |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Conditions | Multiple myeloma |
| Interventions | Patients will be randomized on entry between: Arm A: 8 cycles of Melphalan + Prednisone. Arm B: 8 cycles of Melphalan + Prednisone + Thalidomide. Non responders will be taken off protocol treatment after 3 cycles of therapy. If after 8… |
| Registration date | Sep 6, 2005 |
| Target size | 420 |
| Secondary IDs | NL195;NTR232; : Ho49;ISRCTN90692740 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: